MMP9 and cancer: Indeed, as the affinity of the N-TIMP2 and V3 domains of the heterodimer to their targets (MMP-9 and IL-17A, respectively) was not compromised, we attribute the improved ability of the heterodimer to inhibit cancer cell invasion to its ability to simultaneously bind both targets.